At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 13 enrolled
Drug / intervention
Afatinibdrug
Likely dose
Afatinib 40mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Afatinib in Pretreated Patients With Advanced NSCLC Harbouring HER2 Exon 20 Mutations
In Brief
A Phase 2 clinical trial evaluating Afatinib for NSCLC. Completed, enrolled 13 participants across 5 sites in 4 countries.
Detailed Summary
The purpose of this study is to investigate the control of disease in pretreated patients with advanced non small cell lung cancer (NSCLC) harbouring HER2 exon 20 mutations as well as the safety and tolerability (how severe the side effects are) of the treatment with afatinib.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNSCLC
CountriesGermany, Netherlands, Spain, Switzerland
Collaborators--
Timeline
Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedFeb 2015
Enrollment StartSep 2015
Primary CompletionSep 2017
TodayJul 2026
First PostedFeb 24, 2015
Enrollment StartSep 16, 2015
Primary CompletionSep 15, 2017
TodayJul 2, 2026
Enrollment to primary: 2.0 yearsPosted 11.4 years ago
Interventions
Afatinibdrug
40mg p.o./ day until documented progression or unacceptable toxicity